133 related articles for article (PubMed ID: 37991998)
1. Correction to: IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
Am J Clin Pathol; 2024 Jan; 161(1):107. PubMed ID: 37991998
[No Abstract] [Full Text] [Related]
2. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
McQuaid DC; Katz SG; Xu ML
Am J Clin Pathol; 2022 Aug; 158(2):173-176. PubMed ID: 35460405
[TBL] [Abstract][Full Text] [Related]
3. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
5. Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas. A clinicopathologic analysis of six cases.
Paulli M; Rosso R; Kindl S; Boveri E; Bonoldi E; Stracca V; Motta T; Arrigoni G; Lazzarino M; Menestrina F
Cancer; 1994 Feb; 73(3):541-9. PubMed ID: 8299075
[TBL] [Abstract][Full Text] [Related]
6. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
7. Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.
Noorduyn LA; de Bruin PC; van Heerde P; van de Sandt MM; Ossenkoppele GJ; Meijer CJ
J Clin Pathol; 1994 Jan; 47(1):33-7. PubMed ID: 8132806
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
[TBL] [Abstract][Full Text] [Related]
9. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
Bisig B; de Reyniès A; Bonnet C; Sujobert P; Rickman DS; Marafioti T; Delsol G; Lamant L; Gaulard P; de Leval L
Haematologica; 2013 Aug; 98(8):1250-8. PubMed ID: 23716562
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients.
Beljaards RC; Meijer CJ; Scheffer E; Toonstra J; van Vloten WA; van der Putte SC; Geerts ML; Willemze R
Am J Pathol; 1989 Dec; 135(6):1169-78. PubMed ID: 2556926
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
[TBL] [Abstract][Full Text] [Related]
12. CD30 expression in non-Hodgkin's lymphoma.
Piris M; Brown DC; Gatter KC; Mason DY
Histopathology; 1990 Sep; 17(3):211-8. PubMed ID: 2173674
[TBL] [Abstract][Full Text] [Related]
13. CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas.
Carminato A; Tecilla M; Roccabianca P; Zanardello C; Melchiotti E; Capello K; Vascellari M
Vet Pathol; 2020 Jan; 57(1):49-55. PubMed ID: 31640480
[TBL] [Abstract][Full Text] [Related]
14. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
15. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.
Martinez A; Pittaluga S; Rudelius M; Davies-Hill T; Sebasigari D; Fountaine TJ; Hewitt S; Jaffe ES; Raffeld M
Am J Surg Pathol; 2008 Aug; 32(8):1190-200. PubMed ID: 18580679
[TBL] [Abstract][Full Text] [Related]
16. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.
Debliquis A; Baseggio L; Bouyer S; Guy J; Garnache-Ottou F; Genevieve F; Mayeur-Rousse C; Letestu R; Chapuis N; Harrivel V; Bennani H; Lachot S; Loosveld M; Nicolino-Brunet C; Pérès M; Roussel M; Veyrat-Masson R; Jacob MC; Drenou B
Cytometry B Clin Cytom; 2021 Jul; 100(4):488-496. PubMed ID: 32803917
[TBL] [Abstract][Full Text] [Related]
17. BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas.
Carbone A; Gloghini A; Gaidano G; Dalla-Favera R; Falini B
Blood; 1997 Sep; 90(6):2445-50. PubMed ID: 9310496
[TBL] [Abstract][Full Text] [Related]
18. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
19. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
20. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
